IRESSA™ In Combo with Xeloda™ in Advanced Colorectal Cancer Patients after 1st-Line Chemo Failure

Study identifier:1839IL/0505

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I/II, Multicentre Clinical Study Of ZD1839 (Iressa™) In Combination With Capecitabine (Xeloda™) In Subjects With Advanced Colorectal Carcinoma After Failure Of First-Line Chemotherapy

Medical condition

Colorectal Cancer

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Gefitinib and capecitabine

Sex

All

Actual Enrollment

40

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Feb 2004
Primary Completion Date: -
Study Completion Date: 01 Nov 2005

Study design

Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria